-
Jun 18 |
Diagnostics World | Researchers from Japan have developed a machine learning framework called DiSPAH (Disease-progression Speed and Pathway Analysis based on a Hidden Markov model) to estimate both the pathway and speed of disease progression in individual patients.
More
-
Jun 16 |
Diagnostics World | Researchers at Stanford University have developed a blood test that reveals the functional age of your organs, predicting the odds of specific organ diseases within ten years, and opening new diagnostic avenues. In a study published in Nature Medicine, researchers showed that not only our organs, but individual cell types within those organs, can be classified by biological rather than chronological age, revealing even more precise data enabling potentially superior diagnostic approaches.
More
-
Jun 11 |
Diagnostics World | A single laboratory-developed blood test, years in the making at The University of Texas MD Anderson Cancer Center, could soon be a clinical reality for determining the risk of nine different cancers. In collaboration with UT MD Anderson, Quest Diagnostics is developing and validating the test based on a handful of circulating protein biomarkers associated with high risk for one or more of the cancers, including colorectal, lung, breast, pancreatic, ovarian, liver, prostate, esophageal, and stomach.
More
-
Jun 10 |
Diagnostics World News | A pair of molecular diagnostics leaders and biotech innovators are building on their track record of fitting science to an unmet clinical need tied to the patient journey with a vaginal swab for detecting—or sometimes more importantly, ruling out—endometrial cancer in women with abnormal postmenopausal bleeding.
More
-
Jun 08 |
Diagnostics World News | Illumina plans a new portfolio of whole genome sequencing oncology research offerings, starting with a kit for molecular residual disease (MRD) research that the company hopes will enable more labs to adopt MRD detection for clinical research. The MRD research solution is available today for early access to select partners and will launch for global customers next year.
More
-
Jun 04 |
Diagnostics World News | A prominent urologic oncologist has helped develop a urine test found to be strikingly predictive of bladder cancer recurrence among patients undergoing surgery followed by BCG therapy, the current gold standard treatment regimen. The liquid biopsy also tends to identify recurrence risk that is missed by routine cystoscopy exams.
More
-
Jun 02 |
Diagnostics World News | At last month's Bio-IT World Conference & Expo, the opening plenary session featured an intimate series of paired conversations, each designed to place a different set of puzzle pieces on the table, examining that puzzle from four distinct vantage points — patient experience, AI-assisted diagnostics, venture investment, and policy reform — with each conversation delivering a bit more clarity to the emerging picture.
More
-
May 29 |
Diagnostics World News | Myriad Genetics launches the Prolaris + AI Test for prostate cancer; Lucent Diagnostics announce a collaboration with Tempus AI; Oxford Nanopore Technologies and Lonza launch new technology to modernize and accelerate GMP quality control testing for mRNA therapeutics; and more.
More
-
May 27 |
Diagnostics World News | At Scope X, Novo Nordisk gave a presentation on how high-impact opportunities for leveraging AI across the pharmaceutical R&D cycle are too numerous to count but won’t “automagically” solve any of the longstanding problems in ushering molecules to market. AI requires human attention to match tools to tasks for ensuring the accuracy of model predictions, and the pitfalls are dangerously easy to miss,
More
-
May 26 |
Diagnostics World News | Isomorphic Labs plans to continue development and deployment of its AI drug design engine; NVision expands POLARIS platform into quantum computation; Kanvas Biosciences advances commercial partnerships that leverage the company’s spatial imaging and manufacturing platform; and more.
More
-
Jun 22 |
UniQure plans to submit its Huntington’s disease gene therapy, AMT-130, for FDA approval after reaching agreement with the agency on using three years of clinical data. The therapy demonstrated a 75% slowdown in disease progression among patients receiving the higher dose. The development marks a major shift in the FDA’s stance following recent leadership changes and is being viewed as a positive signal for the broader cell and gene therapy sector. Following the announcement, UniQure shares surged nearly 80%, reflecting renewed investor confidence in the program and its regulatory pathway.
More
-
Jun 22 |
New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates
More
-
Jun 22 |
Spot Biosystems has emerged from stealth with $40 million in funding and a breakthrough non-viral gene therapy platform for Duchenne muscular dystrophy (DMD). The company demonstrated the world's first successful delivery of full-length dystrophin to human skeletal muscle using engineered extracellular vesicles (EVs). Early clinical data showed dystrophin increases of over 1,000% and 2,000% in two pediatric DMD patients, along with improved muscle function. The technology aims to overcome the limitations of traditional viral gene therapies by enabling repeat dosing and larger genetic payload delivery.
More
-
Jun 18 |
Biogen has agreed to acquire RayThera in a deal worth up to $1 billion, significantly expanding its immunology pipeline and strengthening its presence in immune-mediated disease research. The acquisition brings multiple anti-inflammatory drug candidates to Biogen, including a lead therapy expected to enter Phase 1 clinical trials in Q3 2026. Once the transaction closes, Biogen will oversee the development, manufacturing, and global commercialization of these assets. The deal reflects Biogen’s long-term strategy to accelerate innovation and advance new treatment options in immunology.
More
-
Jun 18 |
Built on a new AI-native architecture, Concentriq delivers clinically and scientifically grounded intelligence to decisions throughout drug discovery, development, and case review
More
-
Jun 16 |
Novo Nordisk's Wegovy® pill has become the first daily GLP-1 weight-loss tablet approved in the UK, offering adults with obesity and overweight a convenient alternative to weekly injections. The approval was based on the Phase 3 OASIS 4 trial, where patients achieved up to 16.6% average weight loss over 64 weeks. As obesity affects around 15 million people in the UK, the launch of this oral semaglutide treatment is expected to expand access to effective obesity care and strengthen the growing role of GLP-1 drugs in long-term weight management.
More
-
Jun 15 |
Roche has received FDA approval for the VENTANA PTEN (SP218) RxDx Assay, the first companion diagnostic test designed to identify PTEN protein loss in patients with prostate adenocarcinoma. The breakthrough test helps clinicians determine which patients may benefit from AstraZeneca’s targeted therapy TRUQAP (capivasertib), advancing personalized cancer treatment. Supported by results from the CAPItello-281 clinical trial, the approval marks a significant step in precision oncology, offering new hope for patients with aggressive PTEN-deficient metastatic prostate cancer while reinforcing Roche’s leadership in companion diagnostics and personalized healthcare solutions.
More
-
Jun 15 |
The WID®-easy test has now been included in the updated German S3 Guideline on Endometrial Cancer (Version 4.0, May 2026, AWMF 032-034OL). It is referenced in the explanatory background text supporting the recommendations, on pages 67 and 68.
Key points at a glance:
• The guideline cites four peer-reviewed validation studies and describes a reduction of invasive workup from 19 to 2 D&C procedures per cancer detected, compared with transvaginal ultrasound alone.
• On the basis of the cited studies, the guideline attributes to the WID®-easy Test a sensitivity of > 95 % and a negative predictive value, NPV, of ≥ 99.7 %.
• The guideline states that the WID®-easy Test "has the potential to improve the diagnostic workup of women with peri- and postmenopausal bleeding by reducing the rate of invasive procedures."
The full guideline (in German) is available here:
https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Endometriumkarzinom/Version_4/LL_Endometriumkarzinom_Langversion__4.0.pdf
Please note that the guideline itself is only available in German.
The summary above reflects the relevant statements from pages 67–68.
More
-
Jun 15 |
MRC Holland is announcing the launch of our latest assay: NXtec™ D008 DMD. This NGS-based solution delivers highly reliable detection of CNVs associated with Duchenne and Becker muscular dystrophies.
NXtec D008 DMD is a high-throughput assay providing comprehensive coverage of DMD with two probes per each of its 79 exons, and 50 additional probes distributed across the X chromosome to aid with result interpretation. It enables the detection of single-exon to whole-gene CNVs in DMD, as well as larger X-chromosome CNVs and aneuploidies in a single reaction.
More
-
Jun 12 |
CEPI has committed $60 million to accelerate Ebola Bundibugyo vaccine development with Moderna and the University of Oxford amid an ongoing outbreak in the Democratic Republic of Congo. The funding will support preclinical and early clinical development, along with manufacturing readiness for potential large-scale trials. Health agencies report 282 confirmed cases and 42 deaths, highlighting urgent containment needs. The initiative strengthens global vaccine R&D efforts focused on faster outbreak response and infectious disease preparedness.
More
View more articles